No Data
No Data
Express News | Shanghai Kaibao: Plans to invest in the construction of a modern Chinese medicine intelligent manufacturing industrialization project
Shanghai Kaibao (300039.SZ) has been re-certified as a high-tech enterprise
Gelonghui, February 26 | Shanghai Kaibao (300039.SZ) announced that the company successfully passed the high-tech enterprise re-certification and recently received the “High-tech Enterprise Certificate” jointly issued by the Shanghai Municipal Science and Technology Commission, the Shanghai Municipal Finance Bureau, and the Shanghai Taxation Bureau of the State Administration of Taxation. The certificate number is GR202331001517. The certificate number is GR202331001517. The certificate is issued on November 15, 2023 and is valid for three years.
Shanghai Kaibao (300039.SZ): Net profit is expected to increase 45%-85% year-on-year in 2023
On January 30, Ge Longhui | Shanghai Kaibao (300039.SZ) announced that net profit for 2023 is estimated to be 276.6665 million yuan to 35,29883 million yuan, an increase of 45%-85% over the same period last year, after deducting non-net profit of 254.08083 million yuan to 314.423 million yuan, an increase of 41% to 77% over the same period last year. The impact of the company's non-recurring profit and loss on net profit in 2023 is estimated to be around RMB 330.00 million, and the amount of impact of non-recurring profit and loss on net profit in the previous year was RMB 13.211 million.
Shanghai Kaibao (300039.SZ): 93 drugs included in the national medical insurance catalogue
Shanghai Kaibao (300039.SZ) announced that the company and its wholly-owned subsidiary Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd...
Traditional Chinese medicine and anti-influenza concept stocks rallied, Jinling Pharmaceutical rose and stopped
Gelonghui, December 13 | Jinling Pharmaceutical rose and stopped in a straight line, with Shanghai Kaibao, Wohua Pharmaceutical, Zuoli Pharmaceutical, Yisheng Pharmaceutical, and Longshen Rongfa following suit.
Shanghai Kaibao (300039.SZ): “Traditional Chinese Medicine Internal Medicine Clinical Diagnosis and Treatment Guidelines - Mycoplasma Pneumonia” issued by the Chinese Society of Traditional Chinese Medicine. Phlegm fever-clearing injections are listed as
On December 7, Gelonghui, Shanghai Kaibao (300039.SZ) stated on the investor interactive platform that the phlegm fever-clearing series products include: phlegm fever-clearing injections, phlegm fever-clearing capsules, and phlegm fever-clearing oral solutions under development. The main effects of phlegm clearing injections are to clear heat, detoxify, and relieve phlegm. They are mainly used for the treatment of acute and chronic bronchitis, pneumonia, and upper respiratory tract infections caused by bacteria or viruses. Phlegm fever-clearing injections for prevention and control of “human avian influenza,” “influenza A (H1N1),” “influenza A (H7N9),” “hand, foot and mouth disease,” “dengue fever,” “Ebola,” “Middle East respiratory syndrome,” and “COVID-19.”
No Data